MedTrace Logo

Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy

NCT00992290 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-01-07

No results posted yet for this study

Summary

This research proposes to find whether the probiotic lactobacillus GG is safe and well tolerated in patients with minimal hepatic encephalopathy. We also want to get insight into the mechanisms of action of LGG.

Conditions

  • Minimal Hepatic Encephalopathy

Interventions

BIOLOGICAL

Lactobacillus GG

1 capsule of lactobacillus GG BID compared to placebo BID

BIOLOGICAL

Placebo

1 capsule of lactobacillus GG BID compared to placebo BID

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Jasmohan S Bajaj, MD, MSc · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-12-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00992290 on ClinicalTrials.gov